A new study published in this month’s issue of the journal European Neurology, and published online by the U.S. National Institute of Health, has found that Sativex – a medicinal spray made from the cannabis plant – is an effective and safe treatment option for “moderate to severe multiple sclerosis spasticity (MSS)”.
According to researchers: “Nabiximols (Sativex®), a cannabinoid-based oromucosal spray, is an add-on therapy for patients with moderate to severe multiple sclerosis spasticity (MSS) resistant to other medications. The primary objective was to provide real-life observational data of clinical experience of nabiximols in contrast to formal clinical trials of effectiveness.”
Researchers used an “observational, prospective, multicenter, non-interventional” research method with “a follow-up period of 3-4 months”; in total, 335 patients were assessed.
After conducting the study, it was concluded that; “Real-life data confirm nabiximols as an effective and well-tolerated treatment option for resistant MSS in clinical practice.”
The study was conducted by researchers at the Neurological Rehabilitation Center Quellenhof in Germany.
A study published earlier this year by the journal Expert Review of Neurotherapeutics came to a similar conclusion about Sativex, finding it to be an effective treatment for multiple sclerosis spasticity.